Source: Annual Congress 2007 - ISAM - Expanding role of aerosols: systemic drug delivery, gene therapy and vaccination
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Laube (Baltimore, United States of America). Expanding role of aerosols: systemic drug delivery, gene therapy and vaccination. Annual Congress 2007 - ISAM - Expanding role of aerosols: systemic drug delivery, gene therapy and vaccination

Member's Comments

No comment yet.

Related content which might interest you: What the pulmonary specialist should know about the new inhalation therapies Source: Eur Respir J 2011; 37: 1308-1417 Year: 2011 Distribution of technetium-99m-labelled QVARTM delivered using an AutohalerTM device in children Source: Eur Respir J 2003; 21: 1007-1011 Year: 2003 Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Source: Eur Respir J 2011; 38: 1328-1335 Year: 2011 Asthma management - The role of drug delivery Source: Annual Congress 2005 - Asthma management - important issues Year: 2005 GENebu Project: home nebulizer use and maintenance in Italy Source: Eur Respir J 2001; 18: 758-763 Year: 2001 In a rural part of Canada, a study of the treatment of asthma attacks shows an over utilisation of salbutamol nebulization and of antibiotics, a less frequent use of steroid inhalation treatments, a lower incidence of environmental modification teaching a Source: Eur Respir J 2003; 22: Suppl. 45, 409s Year: 2003 Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Systemic availability (lung deposition) of drug from two different dry powder inhalers in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002 Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis) Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD Year: 2018 Targeting small airways in asthma: the new challenge of inhaled corticosteroid treatment Source: Eur Respir J 2008; 31: 1145-1147 Year: 2008 Reduction of treatment time for nebulized treatments using a new adaptive aerosol delivery mode Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 In-vitro emitted dose characteristics of combination budesonide / formoterol tubuhaler using patient inhalation profiles Source: International Congress 2015 – Lung function: waiting to exhale... Year: 2015 Scientific rationale for using a single inhaler for asthma control Source: Eur Respir J 2007; 29: 587-595 Year: 2007 The concept study: comparative influence of two treatment strategies on airway response to AMP Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how? Year: 2005 The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study Source: International Congress 2016 – Kaleidoscope of respiratory nursing Year: 2016 The role of inhaled antibiotics in bronchial infection Source: Eur Respir Monogr 2013; 60: 120-126 Year: 2013 Dose-FEV1 modeling to support future development of AZD2115, a dual acting bronchodilator for the treatment of COPD Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015